Arbutus Biopharma Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABUS Nasdaq 8731 https://www.arbutusbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arbutus Biopharma Corp

Arbutus Announces Resignation of Board Member - Jan 27th, 2023 12:30 pm
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains? - Jan 12th, 2023 3:24 am
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update - Jan 5th, 2023 12:30 pm
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection - Dec 13th, 2022 12:30 pm
Companies Like Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Invest In Growth - Dec 8th, 2022 11:34 am
Arbutus Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 11th, 2022 10:20 am
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates - Nov 9th, 2022 1:45 pm
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 9th, 2022 12:30 pm
Arbutus to Present at Jefferies London Healthcare Conference - Nov 8th, 2022 12:30 pm
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting® - Nov 1st, 2022 8:01 pm
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022 - Oct 31st, 2022 8:02 pm
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update - Oct 26th, 2022 11:30 am
Investors in Arbutus Biopharma (NASDAQ:ABUS) have made a strong return of 105% over the past three years - Oct 9th, 2022 2:05 pm
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End - Sep 30th, 2022 1:00 pm
Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference - Sep 22nd, 2022 11:30 am
Arbutus to Participate in September Investor Conferences - Sep 6th, 2022 11:30 am
Arbutus Biopharma Corporation's (NASDAQ:ABUS) top owners are individual investors with 43% stake, while30% is held by institutions - Sep 6th, 2022 10:54 am
Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729 - Aug 30th, 2022 11:30 am
Analysts Just Shipped A Dazzling Upgrade To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Estimates - Aug 10th, 2022 10:26 am
Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript - Aug 4th, 2022 11:30 pm